AstraZeneca PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZN research report →
Companywww.astrazeneca.com
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
- CEO
- Pascal Claude Roland Soriot
- IPO
- 1993
- Employees
- 94,300
- HQ
- Cambridge, GB
Price Chart
Valuation
- Market Cap
- $290.72B
- P/E
- 27.78
- P/S
- 4.78
- P/B
- 6.13
- EV/EBITDA
- 15.44
- Div Yield
- 1.69%
Profitability
- Gross Margin
- 79.71%
- Op Margin
- 23.53%
- Net Margin
- 17.19%
- ROE
- 22.41%
- ROIC
- 12.88%
Growth & Income
- Revenue
- $58.74B · 8.63%
- Net Income
- $10.26B · 45.77%
- EPS
- $6.60 · 190.75%
- Op Income
- $13.74B
- FCF YoY
- 61.72%
Performance & Tape
- 52W High
- $212.71
- 52W Low
- $137.22
- 50D MA
- $191.56
- 200D MA
- $179.64
- Beta
- 0.22
- Avg Volume
- 1.93M
Get TickerSpark's AI analysis on AZN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 6, 26 | Sharma Mani | other | 1 |
| Apr 7, 26 | Sharma Mani | other | 1 |
| Mar 18, 26 | Sharma Mani | other | 0 |
| Mar 18, 26 | Sharma Mani | other | 2,996.308 |
| Mar 18, 26 | Sharma Mani | other | 31.297 |
| Dec 1, 28 | Sharma Mani | other | 195 |
Our AZN Coverage
We haven't published any research on AZN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AZN Report →